News & Updates
Filter by Specialty:
JAK inhibitors shown safe, effective in RA patients
A recent study has demonstrated the safety and efficacy of oral Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA) in the real-world setting, particularly in those who do not present with cardiovascular risk factors at baseline.
JAK inhibitors shown safe, effective in RA patients
24 Jul 2024Adalimumab concentrations negatively linked to inflammatory markers in RA
A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.
Adalimumab concentrations negatively linked to inflammatory markers in RA
22 Jul 2024High CRP level tied to earlier death in ILD
Increased levels of serum C-reactive protein (CRP) may contribute to shorter survival in patients with idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), or systemic sclerosis (SSc)-associated ILD at 5 years.